asparaginase
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Asparagine.
- Target
- Asparagine
- Mechanism
- Asparagine hydrolytic enzyme
pharma · Leukemia · Acute Myeloid Leukemia
Shanghai Medical College
Children's Hospital of Fudan University
Shanghai Medical College drug portfolio — 22 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
20 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Employees
- 20
- Programs
- 20
- Drugs
- 22
- Patents
- 0
Shanghai Medical College pipeline
Portfolio lens on 22 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shanghai Medical College drug portfolio — 22 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Shanghai Medical College in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
busulfan
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Shanghai Medical College in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
dinutuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Disialoganglioside GD2.
- Target
- Disialoganglioside GD2
- Mechanism
- Disialoganglioside GD2 binding agent
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Shanghai Medical College's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
doxorubicin hydrochloride
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
filgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
imatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Shanghai Medical College's portfolio. Mechanism: Tyrosine-protein kinase ABL inhibitor.
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- Platelet-derived growth factor receptor beta inhibitor
-
US regulatory status: approved. Molecular target: Prostaglandin E2 receptor EP3 subtype.
- Target
- Prostaglandin E2 receptor EP3 subtype
- Mechanism
- Prostanoid EP3 receptor agonist
-
Development asset linked to Shanghai Medical College in public FDA and regional records.
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
temozolomide
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Shanghai Medical College in public FDA and regional records.